Dynamic structural remodeling of LINC01956 enhances temozolomide resistance in MGMT -methylated glioblastoma
Science Translational Medicine · 02.10.2024 · 16 (767)
DOI: 10.1126/scitranslmed.ado1573 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 02.10.2024. Verfasst von Xinyi Liao und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangdong…. Hauptthemen laut MEDLINE: Glioblastoma, Temozolomide, Drug Resistance, Neoplasm, RNA, Long Noncoding. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 81 Literaturangaben.
Abstract (Originalsprache)
The mechanisms underlying stimuli-induced dynamic structural remodeling of RNAs for the maintenance of cellular physiological function and survival remain unclear. Here, we showed that in MGMT promoter–methylated glioblastoma (GBM), the RNA helicase DEAD-box helicase 46 (DDX46) is phosphorylated by temozolomide (TMZ)–activated checkpoint kinase 1 (CHK1), resulting in a dense-to-loose conformational change and an increase in DDX46 helicase activity. DDX46-mediated tertiary structural remodeling of LINC01956 exposes the binding motifs of LINC01956 to the 3′ untranslated region of O 6 -methylguanine DNA methyltransferase ( MGMT ). This accelerates recruitment of MGMT mRNA to the RNA export machinery and transportation of MGMT mRNA from the nucleus to the cytoplasm, leading to increased MGMT abundance and TMZ resistance. Using patient-derived xenograft (PDX) and tumor organoid models, we found that treatment with the CHK1 inhibitor SRA737abolishes TMZ-induced structural remodeling of LINC01956 and subsequent MGMT up-regulation, resensitizing TMZ-resistant MGMT promoter–methylated GBM to TMZ. In conclusion, these findings highlight a mechanism underlying temozolomide-induced RNA structural remodeling and may represent a potential therapeutic strategy for patients with TMZ-resistant MGMT promoter–methylated GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangdong 510060, China.
- Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangdong 510080, China.
- Department of Neurosurgery, First Affiliated Hospital, Sun Yat-sen University, Guangdong 510080, China.
ORCID-Profile: Xinyi Liao, Xincheng Li, Nu Zhang, Libing Song, Jun Li
Zitieren
APA
Liao, X., Zhang, S., Li, X., Qian, W., Li, M., Chen, S., Wu, X., Yu, X., Li, Z., Tang, M., Xu, Y., Yu, R., Zhang, Q., Wu, G., Zhang, N., Song, L., & Li, J. (2024). Dynamic structural remodeling of LINC01956 enhances temozolomide resistance in MGMT -methylated glioblastoma. Science Translational Medicine, 16(767). https://doi.org/10.1126/scitranslmed.ado1573
Vancouver
Liao X, Zhang S, Li X, Qian W, Li M, Chen S, et al. Dynamic structural remodeling of LINC01956 enhances temozolomide resistance in MGMT -methylated glioblastoma. Science Translational Medicine. 2024;16(767). doi:10.1126/scitranslmed.ado1573
BibTeX
@article{Liao2024,
author = {Liao, Xinyi and Zhang, Shuxia and Li, Xincheng and Qian, Wanying and Li, Man and Chen, Suwen and Wu, Xingui and Yu, Xuexin and Li, Ziwen and Tang, Miaoling and Xu, Yingru and Yu, Ruyuan and Zhang, Qiliang and Wu, Geyan and Zhang, Nu and Song, Libing and Li, Jun},
title = {Dynamic structural remodeling of LINC01956 enhances temozolomide resistance in MGMT -methylated glioblastoma},
journal = {Science Translational Medicine},
year = {2024},
volume = {16},
number = {767},
doi = {10.1126/scitranslmed.ado1573}
}
EUVIMED